In stock Batch Verification Description Retatrutide Canada (20mg) Laboratory Research Reagent Retatrutide Canada is supplied as lyophilized material intended for non-clinical laboratory research by qualified facilities and trained personnel
Research-use-only supply questions
SURPASS-CVOT is a phase 3 study enrolled approximately 13,000 patients at least 40 years of age and have a diagnosis of type 2 diabetes, confirmed atherosclerotic cardiovascular disease, HbA1c 7.0% to 10.5% and a body mass index (BMI) 25 kilograms per meter squared (kg/m 2 )
As a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 Treatments, Semaglutide or Tirzepatide mimics the action of the body's natural GLP-1 hormone
More recent analyses of retatrutide also indicate that the observed changes in body composition largely involved a reduction in body fat with relative maintenance of lean mass
Potential for Disordered Eating or Body Dissatisfaction Rapid weight loss can disrupt a persons relationship with food and body